759-05-7Relevant articles and documents
Photoinduced homolytic decarboxylative acylation/cyclization of unactivated alkenes with α-keto acid under external oxidant and photocatalyst free conditions: access to quinazolinone derivatives
Sun, Bin,Shi, Rongcheng,Zhang, Kesheng,Tang, Xiaoli,Shi, Xiayue,Xu, Jiayun,Yang, Jin,Jin, Can
supporting information, p. 6050 - 6053 (2021/06/21)
A novel and green strategy for the synthesis of acylated quinazolinone derivativesviaphoto-induced decarboxylative cascade radical acylation/cyclization of quinazolinone bearing unactivated alkenes has been developed. The protocol provides a novel route to access acyl radicals from α-keto acids through a self-catalyzed energy transfer process. Most importantly, the reaction proceeded smoothly without any external photocatalyst, additive or oxidant, and could be easily scaled-up in flow conditions with sunlight irradiation.
Targeted Covalent Inhibition of Plasmodium FK506 Binding Protein 35
Atack, Thomas C.,Raymond, Donald D.,Blomquist, Christa A.,Pasaje, Charisse Flerida,McCarren, Patrick R.,Moroco, Jamie,Befekadu, Henock B.,Robinson, Foxy P.,Pal, Debjani,Esherick, Lisl Y.,Ianari, Alessandra,Niles, Jacquin C.,Sellers, William R.
supporting information, p. 2131 - 2138 (2020/12/17)
FK506-binding protein 35, FKBP35, has been implicated as an essential malarial enzyme. Rapamycin and FK506 exhibit antiplasmodium activity in cultured parasites. However, due to the highly conserved nature of the binding pockets of FKBPs and the immunosuppressive properties of these drugs, there is a need for compounds that selectively inhibit FKBP35 and lack the undesired side effects. In contrast to human FKBPs, FKBP35 contains a cysteine, C106, adjacent to the rapamycin binding pocket, providing an opportunity to develop targeted covalent inhibitors of Plasmodium FKBP35. Here, we synthesize inhibitors of FKBP35, show that they directly bind FKBP35 in a model cellular setting, selectively covalently modify C106, and exhibit antiplasmodium activity in blood-stage cultured parasites.
Synthesis method of 2-(9H-fluorene-9-methoxycarbonylamino)-3-methyl-2-butenoic acid
-
Paragraph 0006; 0009, (2020/12/30)
The invention relates to a synthesis method of 2-(9H-fluorene-9-methoxycarbonylamino)-3-methyl-2-butenoic acid. The method mainly solves the technical problem of lack of an amplified production methodof 2-(9H-fluorene-9-methoxycarbonylamino)-3-methyl-2-butenoic acid at present. The synthesis method comprises the following steps: in methyl tert-butyl ether cooled in an ice bath, acidifying 3-methyl-2-oxobutyrate with concentrated hydrochloric acid to generate a compound 1; in methylbenzene subjected to heating reflux, the compound 1 and fluorenylmethoxycarbonylamide are subjected to dehydration condensation reaction under the catalytic action of p-toluenesulfonic acid to generate a target compound 2. As a medical intermediate and a dehydroamino acid derivative, 2-(9H-fluorene-9-methoxycarbonylamino)-3-methyl-2-butenoic acid is widely applied to the fields of synthesis of peptide active substances and protein engineering.